bioAffinity Technologies, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-14.9M | $-9.0M | $-7.9M | $-8.2M | $-6.3M |
| Depreciation & Amortization | $504.8K | $605.6K | $249.6K | $10.2K | $4.8K |
| Depreciation | $170.4K | $162.3K | $233.1K | $10.2K | — |
| Amortization | $58.3K | $58.3K | $16.5K | $0 | — |
| Stock-Based Compensation | $671.5K | $989.7K | $748.8K | $248.6K | $43.0K |
| Net Cash from Operating Activities | $-9.3M | $-7.3M | $-6.0M | $-4.1M | $-2.0M |
| Investing Activities | |||||
| Capital Expenditures | $60.6K | $79.1K | $22.9K | $220.0K | — |
| Business Acquisitions | — | — | $2.2M | — | — |
| Net Cash from Investing Activities | $-60.6K | $-79.1K | $-2.2M | $-220.0K | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $14.7M | $5.6M | $-345.0K | $14.3M | $3.3M |
| Net Change in Cash | $5.3M | $-1.7M | $-8.6M | $10.1M | $1.3M |
| Free Cash Flow | $-9.4M | $-7.3M | $-6.1M | $-4.3M | — |